The COVID-19 pandemic is affecting all of us around the world. Abbott is putting its resources towards helping you navigate this crisis. As a leader in diagnostic testing, we have a unique responsibility to contribute our expertise to help fight the COVID-19 pandemic.
To help provide the critical diagnostic information needed, Abbott is currently providing, and continuing to develop, tests across its diagnostic platforms.
We thank you for your patience and understanding as we do our part to manufacture products that help keep communities safe.
The first-of-its-kind NAVICA™ app helps people navigate daily life in a new normal. NAVICA displays results from the 15-minute BinaxNOW™ COVID-19 Ag Card, a rapid antigen test, to help individuals make informed decisions.
The ID NOW™ COVID-19 assay is now available for use on the ID NOW platform under U.S. Food and Drug Administration Emergency Use Authorization (EUA). The ID NOW™ COVID-19 rapid test delivers high-quality molecular positive results in as little as 5 minutes, targeting the coronavirus (COVID-19) RdRp Gene.
Please sign up by clicking on the yellow button below to be notified when testing becomes available in your area.
This form is intended for professionals or administrators. If you would like additional information about product availability and product news, please complete the form below.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage. Not all products are available in all regions. Check with your local representative for availability in specific markets. For In Vitro Diagnostic Use Only. For the use of registered medical practitioners, hospitals and Laboratories only.
Based on your current location, the content on this page may not be relevant for your country.